249 related articles for article (PubMed ID: 26020806)
21. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
[TBL] [Abstract][Full Text] [Related]
22. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
[TBL] [Abstract][Full Text] [Related]
24. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Seto T; Esaki T; Hirai F; Arita S; Nosaki K; Makiyama A; Kometani T; Fujimoto C; Hamatake M; Takeoka H; Agbo F; Shi X
Cancer Chemother Pharmacol; 2013 Sep; 72(3):619-27. PubMed ID: 23892959
[TBL] [Abstract][Full Text] [Related]
25. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Ullenhag GJ; Rossmann E; Liljefors M
PLoS One; 2015; 10(4):e0121197. PubMed ID: 25837499
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J; O'Reilly EM; Middleton MR; Chau I; Hochster H; Fielding A; Burke W; Burris H
Ann Oncol; 2015 Apr; 26(4):804-811. PubMed ID: 25573533
[TBL] [Abstract][Full Text] [Related]
27. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
McKeage MJ; Jameson MB; Ramanathan RK; Rajendran J; Gu Y; Wilson WR; Melink TJ; Tchekmedyian NS
BMC Cancer; 2012 Oct; 12():496. PubMed ID: 23098625
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Hensley ML; Dizon D; Derosa F; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Colevas AD; Spriggs D; Aghajanian C
Invest New Drugs; 2007 Aug; 25(4):335-41. PubMed ID: 17364235
[TBL] [Abstract][Full Text] [Related]
30. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
31. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Botti G; Cortino GR; Di Bonito M; Rubulotta R; Vallone P; Comella G
Oncology; 2002; 62(1):25-32. PubMed ID: 11810040
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
[TBL] [Abstract][Full Text] [Related]
33. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
[TBL] [Abstract][Full Text] [Related]
35. An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.
Marconato L; Finotello R; Bonfanti U; Dacasto M; Beatrice L; Pizzoni S; Leone VF; Balestra G; Furlanello T; Rohrer Bley C; Aresu L
J Vet Intern Med; 2015; 29(2):620-5. PubMed ID: 25818216
[TBL] [Abstract][Full Text] [Related]
36. Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre SJ; Olszanski AJ; Weigang-Köhler K; Riess H; Cohen RB; Wang X; Myrand SP; Wickremsinhe ER; Horn CL; Ouyang H; Callies S; Benhadji KA; Raymond E
Invest New Drugs; 2015 Dec; 33(6):1206-16. PubMed ID: 26377590
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Odenike OM; Sobecks RM; Janisch L; Huo D; Zimmerman TM; Daugherty CK; Ratain MJ; Larson RA
Cancer Chemother Pharmacol; 2004 Dec; 54(6):553-61. PubMed ID: 15349753
[TBL] [Abstract][Full Text] [Related]
38. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
40. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
